WuXi AppTec stock surges after strong first-quarter earnings report

8 articles · Updated · MarketWatch · Apr 28

The Hong Kong-listed shares jumped over 17% to HK$148.00, while Shanghai-listed shares rose 10% after net profit climbed 27% to 4.65 billion yuan and revenue rose 29% to 12.44 billion yuan.
The company credits earnings growth to increased clinical and commercial projects, improved capacity utilization, and optimized production processes, with a rising order backlog reflecting robust customer demand.
Analysts view the results as robust, suggesting WuXi AppTec may achieve or exceed its topline growth guidance, with shares reaching their highest level since December 2021 and marking the largest single-day gain in 18 months.

WuXi's profits are soaring, but is the global drug supply chain facing a breaking point?

The company’s stock just surged. Is a geopolitical storm about to erase these massive gains?

WuXi AppTec is betting billions on Singapore. Will this be enough to reassure nervous global clients?

With US law targeting Chinese biotech, can American drugmakers afford to abandon their key partners?

A US law is shifting $2 billion from China. Who are the biggest winners in this supply chain scramble?